PLK1 and neoplasm: Over the past decade, several Plk1 inhibitors have entered into clinical trials for many different tumor types to evaluate their anti-tumorigenic activity and safety, and these Plk1 inhibitors exhibit promising efficacy and a good safety profile in many of these cancer types.